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Are investigators satisfied with contract 
clinical research in South Africa?
To the Editor: In October 2008, I surveyed 75 principal 
investigators in South Africa with whom I had worked since 
2004. I emailed to each a covering letter, a survey sheet with 
tick boxes for answers to 13 questions, and a comment sheet. I 
received completed surveys from 35 investigators. I could find 
no similar surveys in the literature.
The respondents are experienced investigators, of whom 
66% had more than 5 years’ experience in clinical trials, and a 
further 24% 2 - 5 years’ experience; 37% had taken part in more 
than 5 trials in the previous 12 months, and a further 49% had 
taken part in 2 - 5 trials in the same period.
Investigator meetings were rated as ‘good’ by 51% of the 
investigators, and as ‘average’ by 43%; the supply of study 
materials to the site was rated as ‘good’ by 37% and ‘average’ 
by 57%. Most respondents felt that the general conduct of the 
study was ‘good’ (71%), with nobody rating the conduct as 
‘bad’. The conduct of monitors was rated as ‘good’ by 63% of 
investigators, with nobody rating them as ‘bad’.
Only 14% of investigators rated recruitment at their site as 
‘bad’, while 6% described the sponsor’s expectations of their 
site as ‘bad’. The process of closing a study at the site was rated 
as ‘good’ by 74%.
A preference for electronic case report forms was stated by 
59%, the rest preferring paper forms. Investigator fees were 
described as ‘good’ by 26% of investigators, and ‘average’ by 
57%.
Only 3% of investigators felt that the time to Medicines 
Control Council (MCC) approval was ‘good’, with 80% rating 
the time as ‘bad’.
Contract clinical research in South Africa has grown steadily 
in the last 5 years. This is the only survey that has been 
conducted to determine investigator satisfaction with the 
clinical trial industry. Investigators are generally satisfied with 
the process of conducting clinical research in South Africa, and 
are willing to utilise enhanced technology to stay abreast of the 
rest of the developing world in clinical trials. The time to MCC 
approval remains a concern but, with steps that are under way, 
I am certain that the dissatisfaction will change in the near 
future.
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Kebble or quibble?
Dear Aunt Ethel,
To those skilled at matters surgical, a lost orchid is the 
euphemism for an ectopic testis or undescended testicle. Makes 
Tretchikoff’s originals/collectors’ pieces sound like priceless 
balderdash, perhaps?
Yours affectionately
Robert-Ian Caldwell
Hilton, KwaZulu-Natal
ric@caldwells.co.za   
